Opaleye Management Inc.
An institutional investment manager in BOSTON, MA. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026. SEC CIK 1595855.
- Reported value$1.10bn
- Positions58
Holdings: 58 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Liquidia CorporationLQDA | COM NEW | 53635D202 | 195 | 17.7% | 2,447,500 | Reduced−97,500 | |
| Eton Pharmaceuticals IncETON | COM | 29772L108 | 104 | 9.4% | 2,860,000 | Unchanged | |
| Harrow IncHROW | COM | 415858109 | 102 | 9.2% | 2,400,000 | Reduced−432,230 | |
| Disc Medicine IncIRON | COM | 254604101 | 62.5 | 5.7% | 855,000 | Added+434,000 | |
| Urogen Pharma Ltd | COM | M96088105 | 53.0 | 4.8% | 1,439,996 | Added+9,996 | |
| Apogee Therapeutics Inc | COM | 03770N101 | 51.8 | 4.7% | 390,000 | Unchanged | |
| Meiragtx Holdings plc | COM | G59665102 | 48.0 | 4.3% | 3,550,000 | Added+1,426,741 | |
| Sol-Gel Technologies Ltd | SHS NEW | M8694L137 | 37.1 | 3.4% | 500,000 | Unchanged | |
| Rezolute IncRZLT | COM NEW | 76200L309 | 32.8 | 3.0% | 6,300,000 | Unchanged | |
| TG Therapeutics IncTGTX | COM | 88322Q108 | 29.4 | 2.7% | 535,000 | Unchanged | |
| Immix Biopharma IncIMMX | COM | 45258H106 | 24.2 | 2.2% | 2,345,000 | New+2,345,000 | |
| Crescent Biopharma Inc. | COM | G2545C104 | 23.7 | 2.2% | 1,319,351 | Added+6,736 | |
| Stoke Therapeutics IncSTOK | COM | 86150R107 | 22.9 | 2.1% | 700,000 | Unchanged | |
| Alpha Cognition IncACOG | COM NEW | 02074J501 | 20.9 | 1.9% | 2,895,467 | Added+333,517 | |
| Edgewise Therapeutics IncEWTX | COM | 28036F105 | 20.3 | 1.8% | 500,000 | Unchanged | |
| Revolution Medicines IncRVMD | COM | 76155X100 | 18.7 | 1.7% | 100,000 | Unchanged | |
| Monte Rosa Therapeutics IncGLUE | COM | 61225M102 | 18.0 | 1.6% | 745,000 | New+745,000 | |
| Alumis IncALMS | COM | 022307102 | 15.5 | 1.4% | 550,000 | Unchanged | |
| Codexis IncCDXS | COM | 192005106 | 15.3 | 1.4% | 6,785,000 | Unchanged | |
| Replimune Group IncREPL | COM | 76029N106 | 15.3 | 1.4% | 1,384,993 | New+1,384,993 | |
| Xoma Royalty Corporation | COM NEW | 98419J206 | 14.4 | 1.3% | 338,374 | Added+38,374 | |
| MBX Biosciences IncMBX | COM | 55287L101 | 14.4 | 1.3% | 260,000 | Unchanged | |
| Rhythm Pharmaceuticals IncRYTM | COM | 76243J105 | 13.6 | 1.2% | 122,500 | Reduced−500 | |
| Editas Medicine IncEDIT | COM | 28106W103 | 12.5 | 1.1% | 3,861,930 | Added+1,934,933 | |
| Protagonist Therapeutics IncPTGX | COM | 74366E102 | 12.3 | 1.1% | 100,000 | Unchanged | |
| Cabaletta Bio IncCABA | COM | 12674W109 | 12.0 | 1.1% | 3,863,800 | Added+2,483,800 | |
| Q32 Bio IncQTTB | COM | 746964105 | 11.9 | 1.1% | 931,000 | Reduced−325,228 | |
| Annexon IncANNX | COM | 03589W102 | 9.8 | 0.9% | 1,714,451 | Reduced−617,310 | |
| Verastem IncVSTM | COM NEW | 92337C203 | 6.9 | 0.6% | 1,800,000 | New+1,800,000 | |
| Zentalis Pharmaceuticals IncZNTL | COM | 98943L107 | 6.9 | 0.6% | 1,412,656 | Unchanged | |
| Relmada Therapeutics IncRLMD | COM | 75955J402 | 6.5 | 0.6% | 935,000 | Unchanged | |
| Ocular Therapeutix IncOCUL | COM | 67576A100 | 5.9 | 0.5% | 600,000 | Unchanged | |
| Trevi Therapeutics IncTRVI | COM | 89532M101 | 5.8 | 0.5% | 310,000 | Reduced−35,100 | |
| Bridgebio Oncology TherapeutBBOT | COM NEW | 107924102 | 5.3 | 0.5% | 700,000 | Added+646,718 | |
| Lyell Immunopharma IncLYEL | COM NEW | 55083R203 | 4.8 | 0.4% | 344,025 | Added+264,928 | |
| Opus Genetics IncIRD | COM | 67577R102 | 4.6 | 0.4% | 1,125,000 | Added+5,000 | |
| 4D Molecular Therapeutics inFDMT | COM | 35104E100 | 4.4 | 0.4% | 334,437 | Added+222,146 | |
| Intellia Therapeutics IncNTLA | COM | 45826J105 | 4.2 | 0.4% | 250,000 | Added+5,000 | |
| Voyager Therapeutics IncVYGR | COM | 92915B106 | 4.1 | 0.4% | 1,185,000 | Added+35,000 | |
| Biodesix IncBDSX | COM | 09075X207 | 4.1 | 0.4% | 180,000 | Reduced−58,047 | |
| Rocket Pharmaceuticals IncRCKT | COM | 77313F106 | 3.4 | 0.3% | 1,000,000 | Added+45,000 | |
| Jade Biosciences IncJBIO | COM NEW | 008064206 | 3.2 | 0.3% | 145,000 | Reduced−282,608 | |
| Sanuwave Health IncSNWV | COM | 80303D305 | 3.1 | 0.3% | 306,140 | Reduced−675,127 | |
| Fortress Biotech IncFBIO | COM NEW | 34960Q307 | 2.7 | 0.2% | 890,000 | Reduced−152,000 | |
| Journey Med CorpDERM | COM | 48115J109 | 2.5 | 0.2% | 350,000 | Reduced−610,000 | |
| Phathom Pharmaceuticals IncPHAT | COM | 71722W107 | 2.0 | 0.2% | 185,589 | New+185,589 | |
| Inhibrx Biosciences IncINBX | COM | 45720N103 | 1.9 | 0.2% | 20,291 | New+20,291 | |
| Enanta Pharmaceuticals IncENTA | COM | 29251M106 | 1.8 | 0.2% | 125,000 | Unchanged | |
| Hemab Therapeutics Holdings IncCOAG | COM SHS | 423494103 | 1.8 | 0.2% | 47,652 | New+47,652 | |
| First Tracks BiotherapeuticsTRAX | ORD SHS | 337185102 | 1.3 | 0.1% | 65,000 | New+65,000 | |
| CG Oncology IncCGON | COM | 156944100 | 1.3 | 0.1% | 17,789 | Reduced−77,011 | |
| Biohaven Ltd | COM | G1110E107 | 1.2 | 0.1% | 77,915 | New+77,915 | |
| Atea Pharmaceuticals IncAVIR | COM | 04683R106 | 1.1 | <0.1% | 235,000 | Reduced−87,600 | |
| Pasithea Therapeutics CorpKTTA | COM NEW | 70261F202 | 1.1 | <0.1% | 2,050,000 | New+2,050,000 | |
| ADC Therapeutics SA | SHS | H0036K147 | 0.7 | <0.1% | 700,000 | New+700,000 | |
| Okyo Pharma Ltd | SHS NEW | G6724L116 | 0.6 | <0.1% | 375,204 | New+375,204 | |
| Palatin Technologies IncPTN | COM NEW | 696077601 | 0.2 | <0.1% | 20,500 | New+20,500 | |
| Adagio Med Holdings IncADGM | COM | 00534B100 | 0.0 | <0.1% | 18,444 | Unchanged |
Sold out: 9 positions
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Assertio Holdings Inc | COM NEW | 04546C304 | 0.0 | 0.0% | 0 | Sold out−265,707 | |
| LB Pharmaceuticals IncLBRX | COM SHS | 50180M108 | 0.0 | 0.0% | 0 | Sold out−14,506 | |
| Nextcure IncNXTC | COM NEW | 65343E207 | 0.0 | 0.0% | 0 | Sold out−141,181 | |
| Perspective Therapeutics IncCATX | COM NEW | 46489V302 | 0.0 | 0.0% | 0 | Sold out−4,675,000 | |
| Perspective Therapeutics Inc | CALL | 46489V902 | 0.0 | 0.0% | 0 | Sold out−200,000 | |
| Protalix Biotherapeutics IncPLX | COM | 74365A309 | 0.0 | 0.0% | 0 | Sold out−340,000 | |
| Rigel Pharmaceuticals IncRIGL | COM | 766559702 | 0.0 | 0.0% | 0 | Sold out−70,000 | |
| Sutro Biopharma IncSTRO | COM SHS | 869367201 | 0.0 | 0.0% | 0 | Sold out−190,671 | |
| Tectonic Therapeutic IncTECX | COM | 878972108 | 0.0 | 0.0% | 0 | Sold out−123,000 |
Source: SEC EDGAR, Form 13F-HR, accession 0001420506-26-001803 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.